Navigation Links
Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

HAYWARD, Calif., Jan. 6, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13, 2011, at approximately 11:00 am Pacific Time.J.P. Morgan Healthcare Conference PresentationDate/Time: Thursday, January 13, at 11:00 am Pacific TimeLocation: Westin St. Francis HotelAbout Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2 or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
4. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
(Date:6/22/2016)... ... June 22, 2016 , ... The Immigrant ... achievements and contributions to North Texas and the nation, recently held its annual ... community to the civic and economic vitality of North Texas. Proceeds from the ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
Breaking Biology News(10 mins):